Fibromyalgia syndrome (FMS) is a chronic pain syndrome, characterised by widespread musculoskeletal pain with diffuse tenderness at multiple tender points. Despite intense investigations, the pathophysiology of fibromyalgia (FM) remains elusive. Evidence shows that it could be due to the changes in either the peripheral or central nervous system (CNS). For the CNS changes, alterations in the high brain area of FM patients have been investigated, but the definite mechanisms are still unclear. Magnetic resonance imaging (MRI) and functional MRI have been used to gather evidence regarding the changes of brain morphologies and activities in FM patients. Nevertheless, due to few studies, limited knowledge for alterations in brain activities in FM is currently available. [1] A leading paradigm regarding the pathogenesis of FMS (and similar functional disorders) focuses on the concept of central sensitisation. This concept describes a situation in which there is an increased sensitivity of the CNS to the processing and transmission of pain, leading to the development of clinical phenomena such as allodynia and hyperalgesia.
Fibromyalgia syndrome (FMS) is a chronic pain syndrome, characterised by widespread musculoskeletal pain with diffuse tenderness at multiple tender points. Despite intense investigations, the pathophysiology of fibromyalgia (FM) remains elusive. Evidence shows that it could be due to the changes in either the peripheral or central nervous system (CNS). For the CNS changes, alterations in the high brain area of FM patients have been investigated, but the definite mechanisms are still unclear. Magnetic resonance imaging (MRI) and functional MRI have been used to gather evidence regarding the changes of brain morphologies and activities in FM patients. Nevertheless, due to few studies, limited knowledge for alterations in brain activities in FM is currently available. [1] A leading paradigm regarding the pathogenesis of FMS (and similar functional disorders) focuses on the concept of central sensitisation. This concept describes a situation in which there is an increased sensitivity of the CNS to the processing and transmission of pain, leading to the development of clinical phenomena such as allodynia and hyperalgesia. [2] The hippocampus plays a role in memory and cognitive [3] functions that may be influenced by prolonged stress. The hippocampus also inhibits brain centres associated with the stress response, i.e., the hypothalamic paraventricular nucleus, central amygdala and locus coeruleus. [4] The hippocampus is an integral component of the limbic system, and as such may contribute to the negative affect and avoidance motivation experienced during pain. A substantial body of evidence indicates that the hippocampus processes pain-related information, and some hippocampal neurons respond exclusively following noxious stimulation. [5] Moreover, the hippocampus is vulnerable to damage and is particularly sensitive to the effects of adrenal glucocorticoids secreted during chronic stress. The damaging actions of glucocorticoids under such conditions have been termed allostatic load. [6] Thus, understanding the status of the hippocampus in patients with FM might prove valuable in guiding future investigations, leading to effective therapy. [7] The hippocampus participates in nociception, a function positively correlated with the activity of hippocampal N-methyl-D-aspartate (NMDA). Several stress-related hormones are known to enhance the activity of hippocampal NMDA receptors, increasing excitatory neurotransmission within the hippocampus. [7] Blocking NMDA receptors in the hippocampal formation reduces nociceptive behaviours; this in turn supports the hypothesis that the hippocampal formation is involved in pain-related neural processing and expression of pain-related behaviours. [5] Regional brain metabolism can be monitored by specific metabolic markers using proton magnetic resonance spectroscopy (1H-MRS). MRS has been used for the study of many physiological and pathological processes in the brain and elsewhere. With 1H-MRS, one can detect cerebral metabolites in vivo, most commonly N-acetyl aspartate (NAA) and choline (Cho) and creatine (Cr)-containing compounds. NAA is described as a neuron marker, because it is found at high concentrations almost exclusively in neurons, but is virtually undetectable in various other cell types, including glial cells. [7] In a case-controlled study, we investigated Hippocampus by using 1H-MRS; our hypothesis was that hippocampal dysfunction may be responsible, at least in part, for symptoms seen in patients with FMS. We measured different metabolites NAA and Cho and Cr within the hippocampus in patients with FM and compared the findings with those in healthy controls. In addition we evaluated cognitive function by mini-mental state examination (MMSE) to assess aspects of cognitive functions among patients and controls. Depression assessment was carried out by using the Hamilton depression, while sleep assessment was assessed by structured sleep interview Diagnostic and Statistical Manual of Mental Disorders-IV11, using a sleep diary for 2 weeks.
In our study, we observed that, NAA levels of the right and left hippocampi were lower in the patients compared to controls (P = 0.05 and P < 0.003, respectively), and therefore were statistically significant. Another statistically significant difference was observed in Cho levels in the right hippocampus, which were higher in the patient group; no difference between patient and control groups was found regarding other measured metabolites in hippocampi on both sides. [8] Furthermore, significantly lower NAA/Cho ratios were observed in the right and left hippocampi in the patients compared to controls (P = 0.001 and P = 0.002, respectively). Another significant difference was found between both groups regarding right and left NAA/Cr ratios (right NAA/Cr patients mean + standard deviation (SD) = 1.29a 0.53, control = 2.32 1.1; P = 0.002; left NAA/Cr patients mean + SD = 1.64 + 0.69, control = 2.61 1.6; P = 0.03), while Ch/Cr ratios were not different on both sides. Moreover, significant correlations were found between language scores and right Cho and right Cr levels (P = 0.041 and P = 0.006, respectively), while no other significant correlations were found between different aspects of cognitive functions as assessed by MMSE and other measured metabolites on both sides. [8] Nevertheless, in similar work, Wood et al. [9] investigated bilateral hippocampus of 16 female FM patients in comparison to 8 age-and gender-matched healthy controls using single-voxel 1H-MRS. Their results demonstrated a significant reduction in the ratio of NAA/Cr in FM patients versus matched controls specifically in the right temporal lobe from a voxel centred on the right hippocampus (patient vs. control, mean ± standard deviation: 1.20 ± 0.13 vs. 1.34 ± 0.10, P = 0.03). Moreover, correlation analysis demonstrated a significant negative correlation between patient scores on the FM Impact Questionnaire and NAA/Cr ratio within the right hippocampus (Spearman's rank correlation, r = −0.681, P = 0.018). Their findings indicate that FM is associated with brain metabolite abnormalities within the right hippocampus that correlate with FM symptoms.
To our knowledge, this is the first report that addresses significantly lower NAA, reduced NAA/Cr ratios, and higher Cho levels in the hippocampus as assessed by single-voxel 1H-MRS among patients with FM, compared with controls. Lower hippocampal NAA levels suggest neuronal or axonal metabolic dysfunction, or some combination of these processes. Yet, neuronal loss within the hippocampus was not studied in our series, and this should be assessed in further studies, in order to elucidate whether the reduction in NAA level reflects actual neuronal loss due to atrophic changes within the hippocampus. We suggest that hippocampal dysfunction may be in part responsible for some of the phenomena associated with FM. Our observations are still preliminary, and further studies in larger numbers of patients are needed. Our findings may indicate ways to adoption of new therapeutic strategies for the treatment of patients with this puzzling syndrome.
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